Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Статус неизвестен Россия

CHF201701

Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP testinG, of Heart Failure Therapies

Номер протоколаCHF201701
ФазаФаза не указана
Участников по плану — во всех странах исследования1 800
Сроки11.05.2018 — 01.10.2021
Начало: 11 мая 2018Окончание: 1 октября 2021
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT03412201/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Статус исследования в реестре не указан — уточняйте в центре.
  • Возраст участников: 18–85 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 1800 чел. во всех странах исследования.
  • Центров в реестре: 21 в 9 городах. Список — ниже на странице.
  • Плановая дата окончания (10.2021) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст18–85 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 8 · невключение: 20

Критерии включения

  • Hospital admission within the 72 hours prior to Screening for acute heart failure with dyspnea at rest and pulmonary congestion on chest X-ray, and other signs and/or symptoms of heart failure such as edema and/or positive rales on auscultation.
  • All measures within 24 hours prior to Randomization of systolic blood pressure ≥ 100 mmHg, and of heart rate ≥ 60 bpm.
  • All measures within 24 hours prior to Randomization of serum potassium ≤ 5.0 mEq/L (mmol/L).
  • Biomarker criteria for persistent congestion:
  • At Screening, NT-proBNP > 2,500 pg/mL.
  • At the time of Randomization (within 2 days prior to discharge), NT-proBNP > 1,500 pg/mL (to ensure the persistence of congestion) that has decreased by more than 10% compared to Screening (to ensure the acuity of the index episode).
  • At 1 week prior to admission, at Screening, and at Visit 2 (just prior to Randomization) either (a) <= ½ the optimal dose of ACEi/ARB/ARNi (see Table) prescribed, no beta-blocker prescribed, and <= ½ the optimal dose of MRA prescribed or (b) no ACEi/ARB/ARNi prescribed, <= ½ the optimal dose of beta-blocker prescribed, and <= ½ the optimal dose of MRA prescribed.
  • Written informed consent to participate in the study.

Критерии невключения

  • Age < 18 or > 85 years.
  • Clearly documented intolerance to high doses of beta-blockers.
  • Clearly documented intolerance to high doses of renin-angiotensin system (RAS) blockers (both ACEi and ARB).
  • Mechanical ventilation \[not including continuous positive airway pressure (CPAP)/bilevel positive airway pressure (BIPAP)\] in the 24 hours prior to Screening.
  • Significant pulmonary disease contributing substantially to the patients' dyspnea such as forced expiratory volume during the 1st second (FEV1)< 1 liter or need for chronic systemic or nonsystemic steroid therapy, or any kind of primary right heart failure such as primary pulmonary hypertension or recurrent pulmonary embolism.
  • Myocardial infarction, unstable angina or cardiac surgery within 3 months, or cardiac resynchronization therapy (CRT) device implantation within 3 months, or percutaneous transluminal coronary intervention (PTCI), within 1 month prior to Screening.
  • Index Event (admission for AHF) triggered primarily by a correctable etiology such as significant arrhythmia (e.g., sustained ventricular tachycardia, or atrial fibrillation/flutter with sustained ventricular response >130 beats per minute, or bradycardia with sustained ventricular arrhythmia <45 beats per minute), infection, severe anemia, acute coronary syndrome, pulmonary embolism, exacerbation of chronic obstructive pulmonary disease (COPD), planned admission for device implantation or severe non-adherence leading to very significant fluid accumulation prior to admission and brisk diuresis after admission. Troponin elevations without other evidence of an acute coronary syndrome are not an exclusion.
  • Uncorrected thyroid disease, active myocarditis, or known amyloid or hypertrophic obstructive cardiomyopathy.
  • History of heart transplant or on a transplant list, or using or planned to be implanted with a ventricular assist device.
  • Sustained ventricular arrhythmia with syncopal episodes within the 3 months prior to screening that is untreated.
  • Presence at Screening of any hemodynamically significant valvular stenosis or regurgitation, except mitral or tricuspid regurgitation secondary to left ventricular dilatation, or the presence of any hemodynamically significant obstructive lesion of the left ventricular outflow tract.
  • Active infection at any time during the AHF hospitalization prior to Randomization based on abnormal temperature and elevated white blood cells (WBC) or need for intravenous antibiotics.
  • Stroke or transient ischemic attack (TIA) within the 3 months prior to Screening.
  • Primary liver disease considered to be life threatening.
  • Renal disease or estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2 \[as estimated by the simplified Modification of Diet in Renal Disease (MDRD) formula\] at Screening or history of dialysis.
  • Psychiatric or neurological disorder, cirrhosis, or active malignancy leading to a life expectancy < 6 months.
  • Prior (defined as less than 30 days from screening) or current enrollment in a congestive heart failure (CHF) trial or participation in an investigational drug or device study within the 30 days prior to screening
  • Discharge for the AHF hospitalization anticipated to be > 14 days from admission, or to a long-term care facility. Randomization must occur within 12 days following admission and within 2 days prior to anticipated discharge.
  • Inability to comply with all study requirements, due to major co-morbidities, social or financial issues, or a history of noncompliance with medical regimens, that might compromise the patient's ability to understand and/or comply with the protocol instructions or follow-up procedures
  • Pregnant or nursing (lactating) women.

Источник: ClinicalTrials.gov, NCT03412201 · запись обновлена в реестре 12 февраля 2021.

Дизайн и результаты

ДизайнРандомизированное, открытое (без ослепления), параллельные группы; цель — лечение
Участников по плану (все страны)1 800
Результатыбудут после окончания
Что измеряют — первичные конечные точки (1), вторичных — 3
  • 180-day all-cause mortality or heart failure readmission — 180 days

Цель исследования

STRONG-HF is a multicenter, randomized, parallel group study designed to evaluate the efficacy and safety of up-titration of standard oral heart failure medications during hospitalization for acute heart failure. Patients admitted for acute heart failure will be randomized within 2 days before discharge to either usual care or intensification of treatment with a beta-blocker, a renin-angiotensin system blocker, and a mineralocorticoid receptor blocker ("high intensity care" arm). In the "high intensity care" arm, patients' clinical signs and symptoms of heart failure will be assessed, and routine laboratory measures and biomarkers will be measured, at frequent post-discharge visits. When these measures indicate that it is safe to do so, the doses of the oral heart failure medications will be increased to optimal levels. Patients will be followed through 180 days from randomization. Patients assigned to the usual care group will be followed by their general physician and/or cardiologist according to local medical standards. Patients who were screened but did not meet eligibility criteria will be followed for 90-day outcome. Randomized patients will be contacted at 180 days to assess outcomes.

Где проходит

21 центр в 9 городах

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT03412201 Официальный реестр (США) · загружено 9 ноября 2026
    Номер протокола, название, цель, сроки, число участников, спонсор, центры

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.